Inventor · disambiguated record
Utsav Saxena
Also filed as: SAXENA UTSAV
6 granted patents·12 pending applications·4 citations·filing 2018–2025
71Inventor score
Files withDICERNA PHARMACEUTICALS INC9BOEHRINGER INGELHEIM INT3NOVO NORDISK AS2NOVO NORDISK HEALTHCARE AG2DICEMA PHARMACEUTICALS INC1
Top patents by PatentIndex Score
18 records- 0193US11661604B2Methods and compositions for inhibiting expression of LDHADICERNA PHARMACEUTICALS INC·Filed 2020·Granted May 30, 2023·3 cites·20 claims
- 0280US11286488B2Methods and compositions for inhibiting expression of LDHADICERNA PHARMACEUTICALS INC·Filed 2018·Granted Mar 29, 2022·1 cites·25 claims
- 0379US2025283091A1Methods and compositions for inhibiting expression of ldhaNOVO NORDISK HEALTHCARE AG·Filed 2025·Application pending·0 cites
- 0478US2024401059A1Compositions and methods for modulating pnpla3 expressionDICERNA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0577US2024182901A1Methods and compositions for inhibiting expression of ldhaNOVO NORDISK HEALTHCARE AG·Filed 2022·Application pending·0 cites
- 0676US2025092403A1Compositions and methods for inhibiting ketohexokinase (khk)DICERNA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0773US12234456B2Compositions and methods for modulating APOC3 expressionDICERNA PHARMACEUTICALS INC·Filed 2022·Granted Feb 25, 2025·0 cites·11 claims
- 0872US12084662B2Compositions and methods for modulating PNPLA3 expressionDICERNA PHARMACEUTICALS INC·Filed 2022·Granted Sep 10, 2024·0 cites·3 claims
- 0967US11578329B2Compositions and methods for inhibiting nuclear receptor subfamily 1 group H member 3 (NR1H3) expressionNOVO NORDISK AS·Filed 2022·Granted Feb 14, 2023·0 cites·30 claims
- 1066US2023220398A1Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expressionNOVO NORDISK AS·Filed 2023·Application pending·0 cites
- 1165US2024150768A1Methods for the treatment of nash with advanced fibrosis and/or cirrhosisBOEHRINGER INGELHEIM INT·Filed 2023·Application pending·0 cites
- 1263US2025263701A1Compositions and methods for modulating apoc3 expressionDICERNA PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1363US2022340909A1Compositions and methods for inhibiting ketohexokinase (khk)BOEHRINGER INGELHEIM INT·Filed 2022·Application pending·0 cites
- 1461US2024139230A1Dosage regimen for the treatment of nashBOEHRINGER INGELHEIM INT·Filed 2023·Application pending·0 cites
- 1560US2023416752A1Chemical modifications for inhibiting expression of aldh2DICERNA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1657US2023287425A1Compositions and methods for inhibiting angptl3 expressionDICERNA PHARMACUTICALS INC·Filed 2021·Application pending·0 cites
- 1756US11661603B2Compositions and methods for inhibiting ALDH2 expressionDICERNA PHARMACEUTICALS INC·Filed 2019·Granted May 30, 2023·0 cites·25 claims
- 1847US2022186229A1Methods and compositions for inhibiting expression of cyp27a1DICEMA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Utsav Saxena files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →